Cyprumed
Cyprumed is a drug delivery technology company based in Innsbruck, Austria. The company focuses on developing technology platforms for the oral administration of therapeutic peptides, including GLP‑1 analogues, macrocycles and mini-proteins. Cyprumed’s proprietary delivery platforms feature innovative tablet formulations that offer superior oral bioavailability and build on already approved pharmaceutical excipients, thus improving scalability, cost-efficiency and regulatory compliance. Cyprumed aims to transform peptide therapeutics by providing easy to manufacture, patient-friendly oral dosage forms. Content by Cyprumed
| 4 min read
MSD initiates a Phase 1 trial of Cyprumed's oral peptide platform designed to reduce food-effect variability
| 1 min read
Cyprumed GmbH and MSD have entered a non-exclusive agreement to develop oral peptide formulations using Cyprumed’s delivery technology.
Page 1 of 1 - 2 Total Items
